ChemoMetec stock
CHEMM.COCPHChemoMetec A/S, HealthcareISIN DK0060055861
78Score 78 out of 100, Strong
Price and trend
85 / 100
Price history
−12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 54% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 71).
The price is 12% below its 52-week high. Largest decline in 20 years: 88% (October 2007 to December 2012).
Chart figures for advanced users
- SMA 50$85.07
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$65.80
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$35.10
- The lowest closing price of the last twelve months.
- Resistance$115.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ChemoMetec A/S belongs to the Medical (Devices) industry (Denmark) and, with a market value of $1.76B, is number 43 of 88 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $75.76M (up 3.1% year on year) and earnings of $29.92M (up 8.3%).
- For fiscal 2027, analysts expect on average revenue of $88.9M (up 17.4%) and adjusted earnings per share of $2.15 (up 25.2%).
Show more
- MEQIRI Score 78 out of 100 (Strong): rank 33 of 702 in Healthcare, median 53.
- The P/E is 59 (Medical (Devices) median 29.1, own median of recent years 56.8).
- Our model puts fair value at $61.65, with the price 65% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 50.7% in fiscal 2026, Medical (Devices) median 5.4%.Profitability 98
- High marginNet margin 39.5% over the last 12 months, Medical (Devices) median 3.2%.Profitability 98
- More cash than debtCash $43.52M, financial debt $680.24K.Stability 80
Weaknesses
- Volatile share priceVolatility 64% a year over the last 12 months.
Its standout strengths are profitability and fundamentals, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 77 to 78.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $41.10 and expensive above $123.30 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $73.31 (cash-flow model) and $49.98 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $55.09, at 6.2% it would be $71.53.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 3.1% on the prior year. Revenue has grown strongly since 2007, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 95%, operating 49%, net 39%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 10 Sep 2026EPS reported $0.92 (expected $0.86)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 12.9% since 15 Oct 2026.
- Earnings per share
- $2.15+12.9%
- Revenue
- $88.9M+4.9%
- Earnings per share
- $2.58+8.5%
- Revenue
- $103.3M+3.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at ChemoMetec
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- ElektaEKTA-B.ST $2.27B56
- Establishment Labs HoldingsESTA $2.05B41
- Butterfly NetworkBFLY $1.78B45
- Embla Medical hf.EMBLA.CO $1.76B67
- Inspire Medical SystemsINSP $1.75B52
- Medartis HoldingMED.SW $1.63B55
- EnovisENOV $1.59B45
- VitrolifeVITR.ST $1.57B51
ETFs that hold ChemoMetec
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.21% | 0.23% | €321.86M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.18% | 0.40% | €1.5B |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.15% | 0.38% | €86.74M |
Show 5 more
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.09% | 0.30% | €3.45B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.03% | 0.30% | €813.64M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.27B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.